Boyce Sarah
- SEC CIK
- 0001629383
In the past year, 2 open-market sale filings worth $1.66M and no purchases.
Current role at each company
- RNA Atrium Therapeutics, Inc.Directoras of Sep 22, 2026
- CTNM Contineum Therapeutics, Inc.Directoras of Jun 26, 2026
- Avidity Biosciences, Inc.President and CEOas of Feb 27, 2026
- OABI OmniAb, Inc.Directoras of Jun 21, 2024
- LGND Ligand Pharmaceuticals IncOther: Former Directoras of Nov 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $1.66M
- 2 filings
- Net
- −$1.66M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Boyce Sarah as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
Avidity Biosciences, Inc.
President and CEO21 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Boyce SarahPresident and CEO | SSale | −100 | $22.47 | −$2.25K | −100.0%0 after | |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Boyce SarahPresident and CEO | SSale | −49.9K | $22.88 | −$1.14M | −100.0%0 after | 2 lots |
| Feb 3, 2023 (view filing) | Feb 1-3 | 2 days | Boyce SarahPresident and CEO | SSale | −50.0K | $24.35 | −$1.22M | −48.4%53.4K after | 3 lots |
| Jan 23, 2024 (view filing) | Jan 22 | 1 day | Boyce SarahPresident and CEO | SSale | −5.09K | $10.13 | −$51.6K | −10.4%44.0K after | 10b5-1 |
| Mar 5, 2024 (view filing) | Mar 1 | 4 days | Boyce SarahPresident and CEO | SSale | −84.0K | $20.13 | −$1.69M | −42.8%112.1K after | 10b5-1 |
| Mar 12, 2024 (view filing) | Mar 8-12 | 4 days | Boyce SarahPresident and CEO | SSale | −112.0K | $21.70 | −$2.43M | −50.0%112.1K after | 2 lots10b5-1 |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Boyce SarahPresident and CEO | SSale | −28.0K | $26.25 | −$735.0K | −20.0%112.1K after | 10b5-1 |
| May 7, 2024 (view filing) | May 7 | Same day | Boyce SarahPresident and CEO | SSale | −28.0K | $25.54 | −$715.1K | −20.0%112.1K after | 10b5-1 |
| Jun 5, 2024 (view filing) | Jun 4 | 1 day | Boyce SarahPresident and CEO | SSale | −28.0K | $27.42 | −$767.8K | −20.0%112.1K after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 12-14 | 2 days | Boyce SarahPresident and CEO | SSale | −300.0K | $38.63 | −$11.6M | −72.8%112.1K after | 3 lots10b5-1 |
OABI OmniAb, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2022 (view filing) | Nov 9-10 | 5 days | Boyce SarahDirector | PPurchase | +36.0K | $2.82 | +$101.3K | New position36.0K after | 2 lots |